trimethyl-isopentyl-ammonium hydroxide | 114328-82-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trimethyl-isopentyl-ammonium hydroxide
• 英文别名: Trimethyl-isopentyl-ammoniumhydroxyd；Trimethyl-isoamyl-ammoniumhydroxyd；Trimethylisoamylammonium；Trimethyl(3-methylbutyl)azanium
• CAS: 114328-82-4
• 化学式: C₈H₂₀N
• 分子量: 130.254
• InChiKey: ISLHZYHURDAPAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  trimethyl-isopentyl-ammonium hydroxide 生成 N,N,3-三甲基丁烷-1-胺
  参考文献：
  名称：

  Collie; Schryver, Journal of the Chemical Society, 1890, vol. 57, p. 774

  摘要：

  DOI：

文献信息

• EFTU INHIBITORS OR AMINOTHIAZOLES AND THEIR USES
  申请人：LaMarche Matthew J.

  公开号：US20080221142A1

  公开（公告）日：2008-09-11

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME
  申请人：Kandula Mahesh

  公开号：US20150080345A1

  公开（公告）日：2015-03-19

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans.

  本发明涉及化学式I和化学式II的化合物或其药学上可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括化学式I或化学式II化合物的有效量的药物组合物，以及用于治疗、预防或调节代谢综合征的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。这些组合物可以用于治疗空腹高血糖、2型糖尿病、空腹血糖受损、糖耐量受损或胰岛素抵抗、高血压、中心性肥胖（也称为内脏、男性型或苹果形脂肪）、腰部脂肪沉积较多的超重、HDL胆固醇降低、甘油三酯升高、高尿酸血症、脂肪肝（尤其是伴有肥胖的进展到NAFLD）、多囊卵巢综合征（女性）、低磷血症、肾脏疾病、蛋白尿、晚期肾脏疾病和棕色糠疹。
• AMINOTHIAZOLES AND THEIR USES
  申请人：Bushell Simon

  公开号：US20140315790A1

  公开（公告）日：2014-10-23

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• MACROCYCLES AND THEIR USES
  申请人：Fujimoto Roger Aki

  公开号：US20090186830A1

  公开（公告）日：2009-07-23

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR
  申请人：Evindar Ghotas

  公开号：US20090318389A1

  公开（公告）日：2009-12-24

  The invention provides compounds formulae I-III, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.

  本发明提供化合物I-III的配方、制备方法以及它们作为药物活性免疫抑制剂的用途，用于治疗自身免疫性疾病、器官移植排斥、与激活免疫系统相关的疾病，以及其他受淋巴减少或SIP受体调节的疾病。